Role of efflux pumps and topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli

Abstract

Point mutations in the topoisomerase (DNA gyrase A) gene are known to be associated with fluoroquinolone resistance in Campylobacter. Recent studies have shown that an efflux pump encoded by cmeABC is also involved in decreased susceptibilities to fluoroquinolones, as well as other antimicrobials. Genome analysis suggests that Campylobacter jejuni contains at least nine other putative efflux pumps. Using insertional inactivation and site-directed mutagenesis, we investigated the potential contributions of these pumps to susceptibilities to chloramphenicol, ciprofloxacin, erythromycin, and tetracycline in C. jejuni and Campylobacter coli. Insertional inactivation of cmeB resulted in 4- to 256-fold decreases in the MICs of chloramphenicol, ciprofloxacin, erythromycin, and tetracycline, with erythromycin being the most significantly affected. In contrast, inactivation of all other putative efflux pumps had no effect on susceptibility to any of the four antimicrobials tested. Mutation of gyrA at codon 86 (Thr-Ile) caused 128- and 64-fold increases in the MICs of ciprofloxacin and nalidixic acid, respectively. The replacement of the mutated gyrA with a wild-type gyrA allele resulted in a 32-fold decrease in the ciprofloxacin MIC and no change in the nalidixic acid MIC. Our findings indicate that CmeABC is the only efflux pump among those tested that influences antimicrobial resistance in Campylobacter and that a point mutation (Thr-86-Ile) in gyrA directly causes fluoroquinolone resistance in Campylobacter. These two mechanisms work synergistically in acquiring and maintaining fluoroquinolone resistance in Campylobacter species.

FIG. 1.

PCR and RT-PCR amplifications of 10 putative efflux pump genes in four Campylobacter strains, C. coli 124 (A), C. coli 241 (B), C. jejuni 81-176 (C), and C. jejuni 81-176ery (D). Lanes 1 are 1-kb DNA markers. Lanes 2 to 11 are 10 putative efflux genes: Cj0035c, Cj0309c-Cj0310c, Cj0366c, Cj0560, Cj0619, Cj1033, Cj1173-Cj1174, Cj1241, Cj1257c, and Cj1687. In the RT-PCR, Cj0309c and Cj1173 instead of Cj0309c-Cj0310c and Cj1173-Cj1174, respectively, were amplified, and 16S rRNA (lane 12) served as a control.